Abstract
The value of antimalarials in the treatment of lupus erythematosus has been well established since Page's article on the use of quinacrine (mepacrine). 1 A recent article by Leeper and Allende 2 compared the use of quinacrine, chloroquine, and amodiaquin for this condition and indicated that the latter two were preferable. Also, light-sensitivity eruptions have been successfully treated and recurrences prevented with quinacrine and chloroquine. 3,4 Another antimalarial preparation under investigation is Plaquenil sulfate (7-chloro-4-[4-N-ethyl-N-β-hydroxyethylamino-1-methylbutylamino]-quinoline). This drug has also been referred to as Win 1258 and is a synthesized stable colorless crystalline solid. It is supplied in tablets of 0.2 and 0.4 gm. It is a 4-aminoquinoline, differing from chloroquine diphosphate in that one of the terminal ethyl groups on the tertiary amino nitrogen is replaced by a hydroxyethyl group. Plaquenil sulfate has been mentioned by several investigators. Goldman 5 felt it was ``certainly less toxic
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
